Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02859324
Title A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Celgene Corporation
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP

Facility Status City State Zip Country Details
UCLA Division of Hematology Oncology Los Angeles California 90095-1752 United States Details
University of Florida Gainesville Florida 32610 United States Details
NYU Langone Medical Center New York New York 10016 United States Details
Mary Crowley Cancer Research Dallas Texas 75251 United States Details
Institut Paoli Calmettes Marseille Cedex 9 13273 France Details
Centre Eugene Marquis Rennes 35200 France Details
Institut Universitaire du Cancer IUCT - Oncopole Toulouse Cedex 31059 France Details
Institut Gustave Roussy Hematologie Villejuif CEDEX 94805 France Details
IRCCS - Istituo Clinico Humanitas - Humanitas Cancer Center Milan 20089 Italy Details
Fondazione IRCCS Policlinico San Matteo Pavia 27100 Italy Details
Istituto Nazionale Tumori Regina Elena Roma 144 Italy Details
Hospital Universitario Vall D Hebron Barcelona 8035 Spain Details
Hospital Ramon y Cajal Madrid 28034 Spain Details
Hospital 12 de Octubre Madrid 28041 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field